

Federico Cucchiara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2848314/publications.pdf>

Version: 2024-02-01

29
papers

415
citations

759233

12
h-index

794594

19
g-index

29
all docs

29
docs citations

29
times ranked

661
citing authors

#	ARTICLE	IF	CITATIONS
1	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1181-1200.	2.3	68
2	Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , 2020, 5, e000919.	4.5	32
3	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 524-531.	3.9	32
4	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	4.2	27
5	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 593831.	2.8	25
6	PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Pharmacological Research</i> , 2021, 163, 105241.	7.1	23
7	erbB in NSCLC as a molecular target: current evidences and future directions. <i>ESMO Open</i> , 2020, 5, e000724.	4.5	22
8	Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?. <i>Pharmacological Research</i> , 2020, 156, 104786.	7.1	21
9	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21
10	Multicenter Study on Sleep and Circadian Alterations as Objective Markers of Mild Cognitive Impairment and Alzheimer's Disease Reveals Sex Differences. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1707-1719.	2.6	20
11	Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188463.	7.4	16
12	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105.	4.4	14
13	Precision Medicine in Lymphoma by Innovative Instrumental Platforms. <i>Frontiers in Oncology</i> , 2019, 9, 1417.	2.8	12
14	A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 182, 113132.	2.8	12
15	Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. <i>Pharmacogenomics Journal</i> , 2021, 21, 233-242.	2.0	11
16	CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 527-533.	2.3	9
17	Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. <i>Pharmacological Research</i> , 2022, 175, 105976.	7.1	8
18	Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103366.	4.4	7

#	ARTICLE	IF	CITATIONS
19	Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3738.	3.7	7
20	Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e331-e333.	2.3	5
21	The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103602.	4.4	5
22	Electrophysiological features of sleep in children with Kir4.1 channel mutations and Autism—Epilepsy phenotype: a preliminary study. <i>Sleep</i> , 2020, 43, .	1.1	4
23	Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. <i>Pharmacological Research</i> , 2022, 181, 106290.	7.1	4
24	Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. <i>Investigational New Drugs</i> , 2020, 38, 92-98.	2.6	3
25	Historical Overview of the “Firing”-Liaison between Brain Tumors and Epilepsy. <i>Neuroscientist</i> , 2022, 28, 411-419.	3.5	2
26	Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples. <i>Separations</i> , 2021, 8, 63.	2.4	2
27	Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival. <i>Clinical Lung Cancer</i> , 2022, 23, 510-521.	2.6	2
28	Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. <i>Pharmacogenomics</i> , 2022, 23, 119-134.	1.3	1
29	1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients. <i>Annals of Oncology</i> , 2020, 31, S1093.	1.2	0